Company news

Actinogen Medical Limited news in 2022

Actinogen Medical Limited's news releases, calls and decks from 2022, newest first.

View company

FDA agrees to six-month Phase 2b Alzheimers Disease Trial

December 22, 2022

First patient treated in XanaCIDD Phase 2 Depression Trial

December 8, 2022

R&D tax incentive rebate received

October 20, 2022

ACW clinical biomarker study webcast presentation

October 9, 2022

ACW announces positive Alzheimers Disease clinical results

October 9, 2022

Actinogen FY22 Results - Accelerating Clinical Development

August 25, 2022

ACW Appendix 4E and 2022 Annual Report

August 25, 2022

ACW CEO presentation to Spark Plus Aust Equities Day

July 27, 2022

Application for quotation of securities - ACW

July 14, 2022

ACW announces Phase 2 trial designs for AD & MDD

June 13, 2022

Actinogen trial results & strategic update presentation

May 3, 2022

Actinogen prioritizes Alzheimers Disease & Depression

May 3, 2022

Quarterly Activity Report & Appendix 4C

April 27, 2022

ACW positive XanaMIA results webcast slide presentation

April 26, 2022

ACW announces positive XanaMIA results for Xanamem

April 26, 2022

Letter to Shareholders & Notice of General Meeting

March 1, 2022

Actinogen Medical: ACW CEO Presents at European Life Sciences Conference

February 28, 2022

Appendix 4D & Half-Year Financial Statements

February 23, 2022

Actinogen XanaMIA Part A trial results expected in April

February 10, 2022

Actinogen appoints XanaFX Phase 2 trial manager

February 8, 2022

Actinogen Medical: ACW CEO Presents at San Francisco Healthcare Conference

January 9, 2022

Decks in 2022